Redeye’s first take on the Q3 report this morning. Cellavision presented a slightly stronger report ...
Redeye sees a Q3 report with solid ACV numbers, but with sales and EBIT hurt by lower Deliveries in ...
Redeye initiates coverage of Curasight, a Danish biotech company offering a theranostics platform (t...
Redeye retains its positive view on Lagercrantz following a Q2 report with strong margins.
SSH Communications Security topline grew 13% y/y with improved profitability with EBITDA margin comi...
Redeye gives a short comment on Ependion’s Q3 2023 report, which came in close to our forecasts, not...
Solid Q3 with 7% organic growth and 8% EBITDA beat vs.
Redeye highlights its key assumptions ahead of the Q3 report, due 9 November.
Atria's Q3 EBIT of EUR 19.3m easily beat Refinitiv consensus, despite a weaker top-line development.
51% beat on EBITDA in Q3 New strategy and mid-term financial targets Earnings revised up for '23e, b...
3 of 4 divisions showed progress in Q3 Scandpower was the outlier with no licence sales '24e EBIT up...
Norway and Denmark are steaming ahead... ...more than offsetting the weaker Sweden Profitability com...
Redeye endorses today’s announcement that CLS’ subsidiary CLS Americas has signed a Mobile Service P...
Sales +1% vs. ABGSCe, EBIT +50% on lower opex Outlook: expects the weak market to linger in the near...
Redeye comments on the latest press releases related to new partnerships/alliances and the news of P...
Redeye updates its view on Acconeer ahead of the Q3 report (due 27 October).
Finnair’s Q3 profitability topped estimates while revenue was much as estimated.
Innofactor’s Q3 results were good and quite as expected despite market headwinds.
XVIVO delivers both improved Gross- and EBITDA margins and an overall organic growth of 42% (CER) wh...
We incorporate the MFG divestment... ...which pushes CEPS up by ~30%.
